Anatara Lifesciences (ASX:ANR) EBIT per Share: A$-0.00 (TTM As of Dec. 2025)


What is Anatara Lifesciences EBIT per Share?

Anatara Lifesciences ASX:ANR EBIT per Share is A$-0.00 as of Dec. 2025. The stock has 5 warning signs investors should review. Among 1,172 Biotechnology companies, Anatara Lifesciences ranks better than 66.55% on this metric.

Anatara Lifesciences's EBIT per Share for the six months ended in Dec. 2025 was A$-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.00.

During the past 3 years, the average EBIT per Share Growth Rate was 28.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was 29.50% per year. During the past 10 years, the average EBIT per Share Growth Rate was 11.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Anatara Lifesciences's EBIT per Share or its related term are showing as below:

ASX:ANR' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -44.9   Med: 19.75   Max: 32.2
Current: 28.9

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Anatara Lifesciences was 32.20% per year. The lowest was -44.90% per year. And the median was 19.75% per year.

ASX:ANR's 3-Year EBIT Growth Rate is ranked better than
66.55% of 1172 companies
in the Biotechnology industry
Industry Median: 15.35 vs ASX:ANR: 28.90

Anatara Lifesciences's EBIT for the six months ended in Dec. 2025 was A$-0.51 Mil.

Anatara Lifesciences  (ASX:ANR) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Anatara Lifesciences EBIT per Share Related Terms

Anatara Lifesciences EBIT per Share Historical Data

* Premium members only.

The historical data trend for Anatara Lifesciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anatara Lifesciences EBIT per Share Chart

Anatara Lifesciences Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.03 -0.02 -0.01 -0.01

Anatara Lifesciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.00 -0.00

Anatara Lifesciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Anatara Lifesciences's EBIT per Share for the fiscal year that ended in Jun. 2025 is calculated as

EBIT per Share(A: Jun. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.947/204.697
=-0.01

Anatara Lifesciences's EBIT per Share for the quarter that ended in Dec. 2025 is calculated as

EBIT per Share(Q: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.512/241.381
=-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of A$-0.00 mean?
Anatara Lifesciences (ASX:ANR) has a EBIT per Share of A$-0.00 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Anatara Lifesciences and its competitors. According to the industry distribution chart, Anatara Lifesciences ranks #392 out of 1172 companies in the Biotechnology industry, placing it in the top 33.4%.
Is Anatara Lifesciences' EBIT per Share too high?
Anatara Lifesciences' current EBIT per Share is A$-0.00. Based on the distribution chart, Anatara Lifesciences ranks #392 out of 1172 companies in the Biotechnology industry, which is above the industry midpoint.
How does Anatara Lifesciences' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anatara Lifesciences ranks #392 out of 1172 companies for EBIT per Share. This puts Anatara Lifesciences in the upper half of its industry. The industry median EBIT per Share is 15.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.35, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Anatara Lifesciences and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anatara Lifesciences's current EBIT per Share is A$-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anatara Lifesciences stock overvalued right now?
Anatara Lifesciences (ASX:ANR) has a current EBIT per Share of A$-0.00. The current EBIT per Share is A$-0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Anatara Lifesciences (ASX:ANR), the current EBIT per Share is A$-0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anatara Lifesciences Business Description

Address c/- Perks, 81 Flinders Street, Level 8, Adelaide, SA, AUS, 5000
Anatara Lifesciences Ltd develops and commercializes evidence-based products addressing unmet needs in gastrointestinal health. The company focuses on building a pipeline of human health products, particularly targeting complex gastrointestinal conditions. It operates through a single reportable segment encompassing the research and development of oral solutions for gastrointestinal diseases and the commercialization of Detach, a diarrhea treatment for piglets.